VAL-DE-REUIL, France--(BUSINESS WIRE)--

ANGANY Genetics, a biotechnology company specialising in the development and production of recombinant allergens for the diagnosis and treatment of allergies, plans to start its new production unit at the PharmaParc II activities park in Val-de-Reuil (Eure) in May.

Until now, the company has been using a prototype-scale production facility but the new functional unit will enable industrial-scale production of a series of purified and optimised allergens starting in the second half of the year. The allergens in question are in particular Der p 1 and Der p 2, which affect 80% of patients with house dust mite allergies, allergens Der p 4 and Der p 7, also for house-mite allergies, and allergens inducing pollen and animal allergies.

These purified and high quality allergens will be made available to pharmaceutical manufacturers for the development of allergen-specific immunotherapy for the treatment of house dust mite and pollen allergies, and later, food and animal dander allergies. As from September 2013 we will be able to meet their requirements in accordance with partnership agreements, indicated Dr Loc Faye, CEO of ANGANY Genetics.

The new manufacturing platform will allow ANGANY Genetics to produce recombinant allergens having a structure identical to that of natural allergens rapidly (12 days) while keeping down costs. Production yields will be at least 5 to 10% of total proteins and may even be as much as 15%, noted Scientific Director, Vronique Gomord.

ANGANY Genetics enjoys the support of the NBA (Normandy Business Angels). Our business angels network was won over both by the scientific expertise of ANGANY Genetics founders, Loc Faye and Vronique Gomord, and by the ability of their scientific platform to deliver an authentic therapeutic solution to the major healthcare issue currently posed by allergies, explained Jacques Gerriet, representative of the Normandy Business Angels and President of the ANGANY Genetics Strategic Committee.

About ANGANY Genetics

ANGANY Genetics is a biotechnology company specialising in the development and production of high quality recombinant allergens for the diagnosis and treatment of allergies. This spin-off from the CNRS and Rouen University was created in April 2010 by two CNRS researchers, Loc Faye and Vronique Gomord, in order to develop applications for their work concerning the production of therapeutic proteins in plants. The company applies its expertise in the fields of plant-based production of biopharmaceuticals and protein engineering to the production of recombinant allergens optimised for use in the diagnosis and treatment of allergies.

About allergies and allergen immunotherapy

Data published by the European Academy of Allergy and Clinical Immunology (EAACI) indicate that over 150 million people in Europe are affected, with 30% of Europeans presenting allergic rhinitis or conjunctivitis and 20% suffering from allergic asthma. The prevalence of allergies is thus growing considerably. Data presented by the EAACI to the European Parliament in the spring of 2012 emphasised that by 2040, 40% of the European population will exhibit a predisposition to allergies. Management of allergies focuses primarily on symptomatic treatments that address the associated manifestations (asthma, rhinitis) but do not tackle the actual source of the problem. The only effective treatment is desensitisation (also termed allergen immunotherapy), which is designed to reduce the patients sensitivity to specific allergens by administering gradually increasing doses of extracts containing the causative allergens administered through subcutaneous injections or sublingual formulations. The quality of the products developed by ANGANY Genetics will allow more specific and more effective desensitisation with a view to personalised treatment of allergies.

Read more from the original source:
ANGANY Genetics Announces the Launch of Its New Production Unit and Gears up for Supply of Its First Allergens for the ...

Comments are closed.